The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that with effect from 8 December 2017, Mr. Meng Xianhui has resigned as an executive Director and ceased to be the chairman of the risk management committee of the company in order to devote more time to other business commitments and engagements. Mr. Meng will remain as a deputy general manager the company. Dr. Zhang Jionglong has resigned as a non-executive Director and ceased to be a member of the audit committee of the company in order to devote more time to other business commitments and engagements. Mr. Choi Yiau Chong has been appointed as an executive Director and the chairman of the Risk Management Committee of the company. Dr. Guo Feng has been appointed as an executive Director of the company. Mr. Kim Jin Ha has been appointed as a non-executive Director and a member of the Audit Committee of the company. Prior to joining Group, Mr. Choi gained his finance and accounting experience at a company listed on the main board of Bursa Malaysia and at Deloitte and Touche. Currently, Mr. Choi is a director of Sun Moral International (HK) Limited since 2017. Mr. Choi is currently the director of certain subsidiaries of the company since 2014. Dr. Guo brought to the Group nearly 20 years of experiences in innovative drug R&D and management especially in oncology drug R&D strategy making, clinical development, registration, etc. drugs. In 2013, Dr. Guo joined Merck & Co. Inc. as Vice President of Global R&D and Head of Merck Biopharma (China) R&D Hub. During his service in Merck, Dr. Guo led his team in clinical development and registration of oncology drugs, including immune-oncology drugs, in China and Asia. In addition, Dr. Guo is an external scientific advisor of the Center for Drug Evaluation of China Food and Drug Administration. Mr. Kim is currently serving as a director of 3NOD Digital Group Co. Ltd.